SCHEMBL254832

SCHEMBL254832

CC1CCC(Cl)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2426255 1.00
SCHEMBL12126946 1.00
SCHEMBL9613647 0.90 EPHX1 (0.30)
SCHEMBL11378272 0.90 EPHX1 (0.30)
SCHEMBL11836323 0.87
SCHEMBL7363310 0.79
SCHEMBL18611198 0.79
SCHEMBL685314 0.79
SCHEMBL18611197 0.79
SCHEMBL9720381 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230340328-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2023-10-26 US disclosed
US-20230340328-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2023-10-26 US disclosed
WO-2023086799-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS VIGIL NEUROSCIENCE, INC. (US) 2023-05-19 WO disclosed
WO-2021226629-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE AMGEN INC. (US) 2021-11-11 WO disclosed
EP-2970114-B1 IDO INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-05-15 EP disclosed
EP-2970155-B1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) BRISTOL MYERS SQUIBB CO (US) 2018-04-25 EP disclosed
WO-2018048969-A1 MULTI-TARGETED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-03-15 WO disclosed
US-9809521-B2 Cannabidinoid derivatives SUTTER WEST BAY HOSPITALS (US) 2017-11-07 US disclosed
US-9802952-B2 Method and apparatus for the synthesis of dihydroartemisinin and artemisinin derivatives Max-Plank-Gesellschaft zur Förderung der Wissenschaften e.v. (DE) 2017-10-31 US disclosed
US-9802952-B2 Method and apparatus for the synthesis of dihydroartemisinin and artemisinin derivatives Max-Plank-Gesellschaft zur Förderung der Wissenschaften e.v. (DE) 2017-10-31 US disclosed
EP-0852225-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND MEDICINAL PREPARATIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT NIPPON STEEL CORPORATION (JP) 1998-07-08 EP disclosed
EP-0800516-A1 FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME NIPPON STEEL CORPORATION (JP) 1997-10-15 EP disclosed
WO-1996020172-A1 FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME NIPPON STEEL CORPORATION (JP) 1996-07-04 WO disclosed
CN-1099740-A Selective catalytic hydrogenation of aromatic aldehydes DEGUSSA (DE) 1995-03-08 CN disclosed
US-5387726-A Selective catalytic hydrogenation of aromatic aldehydes DEGUSSA AKTIENGESELLSCHAFT (DE) 1995-02-07 US disclosed
EP-0606072-A1 Selective catalytic hydrogenation of aromatic aldehydes Degussa Aktiengesellschaft (DE) 1994-07-13 EP disclosed
EP-0352299-A1 RUBRADIRIN DERIVATIVES FOR TREATMENT OF HIV INFECTION THE UPJOHN COMPANY (US) 1990-01-31 EP disclosed
WO-1988008707-A2 RUBRADIRIN DERIVATIVES FOR TREATMENT OF HIV INFECTION THE UPJOHN COMPANY (US) 1988-11-17 WO disclosed
US-4163789-A Anti-psychotic (cycloalkenylalkylpiperidino) benzamides ANPHAR, S.A. (ES) 1979-08-07 US disclosed
US-3971825-A (5,6) (10,11) BIS-METHYLENE, BRONCHODILATORS SANKYO COMPANY LIMITED (JA) 1976-07-27 US disclosed